JTE-607

CAT: 0804-HY-110133-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-110133-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
JTE-607, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively[1]. Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607[2].
CAS Number
[188791-09-5]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jte-607.html
Purity
99.27
Solubility
DMSO : 250 mg/mL (ultrasonic) |H2O : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CCOC([C@H](CC1=CC=CC=C1)NC(C2=C(C(Cl)=C(C(Cl)=C2)OCCN3CCN(CC3)C)O)=O)=O.Cl.Cl
Molecular Formula
C25H33Cl4N3O5
Molecular Weight
597.36
Precautions
H302, H315, H319, H335
References & Citations
[1]M Kakutani, et al. JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48 (8) :461-8.|[2]Nathan T Ross, et al. CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma. Nat Chem Biol. 2020 Jan;16 (1) :50-59.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
IL-10; IL-6; IL-8

Popular Products